Xiaowei Wu

TL;DR: A review of the major research progress in the development of COVID-19 vaccine can be found in this paper, which summarizes and analyzes vaccine progress against SARS-CoV, Middle-East respiratory syndrome Coronavirus (MERS), and SARS CoV-2, including inactivated vaccines, live attenuated vaccines, subunit vaccines, virus like particles, nucleic acid vaccines, and viral vector vaccines.

TL;DR: In this article , the authors identified diverse recombination events between two Omicron major subvariants (BA.1 and BA.2) and other variants of concern (VOCs) and variants of interest (VOIs), suggesting that co-infection and subsequent genome recombination play important roles in the ongoing evolution of SARS-CoV-2.

TL;DR: In this paper, the binding dynamics between SARS-CoV-2 RBD mutants and the human angiotensin-converting enzyme 2 (ACE2) receptor were analyzed in silico.

TL;DR: The analysis of critical RBD mutations provides further insights into the evolutionary trajectory of SARS-CoV-2 under high selection pressure and supports the continuing surveillance of spike mutations to aid in the development of COVID-19 drugs and vaccines.

TL;DR: This work presents an overview of the global promising therapeutic drugs, including repurposing existing antiviral agents, network-based pharmacology research, antibody development and traditional Chinese medicine, and focuses on the most promising drugs that have or will enter the final stage of human testing—phase III–IV clinical trials.